Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
atypical
autonomic dysfunction
cancer associated myopathy
carcinoma
cardiotoxicity
complications
disability, neurological
edema, pedal
finger swelling
fracture, long bone
guanethidine
herpes zoster
iatrogenic neurologic disorders
immune checkpoint inhibitors
immune-related adverse events
ipilimumab
misdiagnosis
monoclonal antibodies
muscle biopsy
muscle pain
muscle weakness
muscle weakness, proximal
myasthenia gravis
myasthenia gravis, drug induced
myocardial infarction
myocarditis
myopathy
myositis
neurologic complications of, systemic cancer
neurologic disease, diagnoses of
neuromuscular junction
neuromuscular junction, abnormality of
neuropathy
nivolumab
osteoporosis
pain
pembrolizumab
physical therapy
prognosis
reflex sympathetic dystrophy
reflex sympathetic dystrophy, children
respiratory failure
review article
skin, discoloration
skin, temperature difference
steroid
sweating, abnormality of
sympathetic block
thermography
trauma
treatment of neurologic disorder
weakness
workup
Showing articles 300 to 350 of 1147 << Previous Next >>

Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Spinal Metastasis and Metastatic Disease to the Spine and Related Structures
eMedicine March, Tse,V., 2009

Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009

CNS Complications of Radiotherapy and Chemotherapy
Lancet 374:1639-1651, Soussain,C.,et al, 2009

Migraine and Cardiovascular Disease: Systematic Review and Meta-Analysis
BMJ 339:b3914, Sch�rks,M.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Moyamoya Disease and Moyamoya Syndrome
NEJM 360:1226-1237, Scott,R.M. &Smith,E.R., 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009

Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Primary Central Nervous System Lymphoma with Cortical Laminar Hemorrhage
J Neurol Sci 287:281-284, Kimura, N.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
J Natl Cancer Inst 101:946-958, Armstrong,G.T.,et al, 2009

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Diabetic Striatal Disease: Clinical Presentation, Neuroimaging, and Pathology
InterMed 48:1135-1141, Abe, Y.,et al, 2009

Concepts and Controversies in Nonketotic Hyperglycemia-Induced Hemichorea: Further Evidence from Susceptibility-Weighted MR imaging
J Magn Reson Imaging 29:699-703, Cherian, A.,et al, 2009

Investigating Severe Interscapular Pain
BMJ 337:a688, Haydar, A.A.,et al, 2008

Embolic Stroke Secondary to Cardiac Papillary Fibroelastoma
Neurologist 14:128-130, Zurru, M.C.,et al, 2008

Venous and arterial thrombo-embolic complications of hormonal treatment in a male-to-female transgender patient
J Clin Neurosci 15:714-716, Mullins, G.M.,et al, 2008

A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008

Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Stroke Location and Association With Fatal Cardiac Outcomes: Northern Manhattan Study (NOMAS)
Stroke 39:2425-2431, Rincon,F.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Update on Blepharospasm: Report from the BEBRF International Workshop
Neurol 71:1275-1282, Hallett,M.,et al, 2008

MR Imaging of Familial Creutzfeldt-Jakob Disease: A Blinded and Controlled Study
AJNR 29:1638-1643, Fulbright,R.K.,et al, 2008

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008

Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression: Summary of NICE Guidance
BMJ 337:1349-1351, White,B.D.,et al, 2008

Patterns of Care in Elderly Glioblastoma Patients
Ann Neurol 64:628-632,597, Iwamoto,F.M.,et al, 2008

Takotsubo Cardiomyopathy in Acute Ischemic Stroke
Ann Neurol 64:547-554, Yoshimura,S.,et al, 2008

Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008

Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008

Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008

Nonadherence to Antiepileptic Drugs and Increased Mortality: Findings from the RANsom Study
Neurol 71:1572-1578, Faught,E.,et al, 2008

A Systematic Review of Outcomes in Patients With Staged Carotid Artery Stenting and Coronary Artery Bypass Graft Surgery
Stroke 39:361-365, Guzman,L.A.,et al, 2008

A 23-Year-Old Man With Seizures and Visual Deficit
Neurol 70:73-78, Boustany,R.-M.,et al, 2008

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008



Showing articles 300 to 350 of 1147 << Previous Next >>